文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

晚期心力衰竭患者左心室辅助装置中的阿司匹林与血液相容性事件:ARIES-HM3随机临床试验

Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项国际随机双盲安慰剂对照研究在9国51中心纳入628例植入全磁悬浮左心室辅助装置的晚期心衰患者,比较阿司匹林100 mg/d与安慰剂联合维生素K拮抗剂治疗。安慰剂组12个月无血液相容性事件生存率74% vs 阿司匹林组68%,非劣效性成立(组间绝对差6.0%,单侧97.5%CI下限-1.6%,P<.001);避免阿司匹林与降低非手术出血事件相关(相对风险0.66,95%CI 0.51-0.85,P=.002),未增加卒中或血栓栓塞事件。

要点

  • 全磁悬浮LVAD患者中,安慰剂联合VKA在12个月无血液相容性事件生存方面非劣效于阿司匹林联合VKA。
  • 避免阿司匹林与降低非手术出血事件相关(相对风险0.66,95%CI 0.51-0.85,P=.002)。
  • 避免阿司匹林未增加卒中或其他血栓栓塞事件,且在不同患者特征亚组中结果一致。

核心结论

  • 在接受全磁悬浮左心室辅助装置治疗的晚期心力衰竭患者中,抗血栓方案中避免阿司匹林(仍包含维生素K拮抗剂)不劣于含阿司匹林的方案,不增加血栓栓塞风险,并与出血事件减少相关。

研究设计与样本

  • 国际、随机、双盲、安慰剂对照研究,比较阿司匹林100 mg/d与安慰剂联合维生素K拮抗剂治疗。
  • 在9个国家51个具备晚期心力衰竭治疗专长的中心开展,2020年7月至2022年9月入组。
  • 随机人群628例植入全磁悬浮左心室辅助装置的晚期心力衰竭患者(安慰剂组314例,阿司匹林组314例),其中安慰剂组296例、阿司匹林组293例进入主要分析人群。
  • 中位随访14个月。

主要发现

  • 主要复合终点为12个月无主要非手术(植入后>14天)血液相容性相关不良事件(包括卒中、泵血栓、大出血或动脉外周血栓栓塞)生存,安慰剂组74% vs 阿司匹林组68%。
  • 安慰剂非劣效性成立:组间绝对差为安慰剂组无事件生存改善6.0%(单侧97.5%CI下限-1.6%;P<.001)。
  • 避免阿司匹林与降低非手术出血事件相关:相对风险0.66(95%CI 0.51-0.85;P=.002)。
  • 未增加卒中或其他血栓栓塞事件,该结果在不同患者特征亚组中一致。
  • 589例分析患者中77%为男性,三分之一为黑人,61%为白人。

临床怎么用

  • 原文结论指出,对于全磁悬浮左心室辅助装置治疗的晚期心力衰竭患者,抗血栓方案中避免阿司匹林(方案包含维生素K拮抗剂)不劣于含阿司匹林的方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Left ventricular assist devices (LVADs) enhance quality and duration of life in advanced heart failure. The burden of nonsurgical bleeding events is a leading morbidity. Aspirin as an antiplatelet agent is mandated along with vitamin K antagonists (VKAs) with continuous-flow LVADs without conclusive evidence of efficacy and safety. OBJECTIVE: To determine whether excluding aspirin as part of the antithrombotic regimen with a fully magnetically levitated LVAD is safe and decreases bleeding. DESIGN, SETTING, AND PARTICIPANTS: This international, randomized, double-blind, placebo-controlled study of aspirin (100 mg/d) vs placebo with VKA therapy in patients with advanced heart failure with an LVAD was conducted across 51 centers with expertise in treating patients with advanced heart failure across 9 countries. The randomized population included 628 patients with advanced heart failure implanted with a fully magnetically levitated LVAD (314 in the placebo group and 314 in the aspirin group), of whom 296 patients in the placebo group and 293 in the aspirin group were in the primary analysis population, which informed the primary end point analysis. The study enrolled patients from July 2020 to September 2022; median follow-up was 14 months. INTERVENTION: Patients were randomized in a 1:1 ratio to receive aspirin (100 mg/d) or placebo in addition to an antithrombotic regimen. MAIN OUTCOMES AND MEASURES: The composite primary end point, assessed for noninferiority (-10% margin) of placebo, was survival free of a major nonsurgical (>14 days after implant) hemocompatibility-related adverse events (including stroke, pump thrombosis, major bleeding, or arterial peripheral thromboembolism) at 12 months. The principal secondary end point was nonsurgical bleeding events. RESULTS: Of the 589 analyzed patients, 77% were men; one-third were Black and 61% were White. More patients were alive and free of hemocompatibility events at 12 months in the placebo group (74%) vs those taking aspirin (68%). Noninferiority of placebo was demonstrated (absolute between-group difference, 6.0% improvement in event-free survival with placebo [lower 1-sided 97.5% CI, -1.6%]; P < .001). Aspirin avoidance was associated with reduced nonsurgical bleeding events (relative risk, 0.66 [95% confidence limit, 0.51-0.85]; P = .002) with no increase in stroke or other thromboembolic events, a finding consistent among diverse subgroups of patient characteristics. CONCLUSIONS AND RELEVANCE: In patients with advanced heart failure treated with a fully magnetically levitated LVAD, avoidance of aspirin as part of an antithrombotic regimen, which includes VKA, is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04069156.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Mehra MR, Netuka I, Uriel N, et al. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial. JAMA. 2023. PMID: 37950897. doi:10.1001/jama.2023.23204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。